TNFRSF17 and Miyoshi myopathy: These lines of evidence provide a strong rationale for evaluating FcRH5 CAR-T cells in treating MM with low or dim BCMA expression at presentation or alternatively relapsing with downregulation or loss of BCMA following BCMA-targeted immunotherapies.